검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Asparaginase (Asparaginase) Johann Wolfgang Goethe University …·Recurrent B Acute Lymphoblastic Le… 31 trials |
|---|---|
Overview Program | Asparaginase |
Overview Company | Johann Wolfgang Goethe University Hospital |
Overview Modality | ANTIBODY |
Overview Target | Recurrent B Acute Lymphoblastic Leukemia |
Overview Indication | Adult Acute Lymphocytic Leukemia |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | target of rapamycin (mTOR), the other major amino acid-sensing pathway |
MoA Biomarker | biomarkers |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Genetic Determinants of Treatment-Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia.. Osteonecrosis and fractures are serious corticosteroid-induced bone toxicities in children treated for acute lymphoblastic leukemia, yet their genetic determinants remain incompletely defined. In this study, we aimed to identify novel genetic contributors to bone toxicity and to evaluate the robustn… |
Clinical OS | 33.6 |
Clinical Result source | ClinicalTrials.gov NCT00061945 |
Clinical Data Tier / Score | A · 44 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Asparaginase (Asparaginase) Johann Wolfgang Goethe University …·Recurrent B Acute Lymphoblastic Le… 31 trials |
|---|---|
Overview Program | Asparaginase |
Overview Company | Johann Wolfgang Goethe University Hospital |
Overview Modality | ANTIBODY |
Overview Target | Recurrent B Acute Lymphoblastic Leukemia |
Overview Indication | Adult Acute Lymphocytic Leukemia |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | target of rapamycin (mTOR), the other major amino acid-sensing pathway |
MoA Biomarker | biomarkers |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Genetic Determinants of Treatment-Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia.. Osteonecrosis and fractures are serious corticosteroid-induced bone toxicities in children treated for acute lymphoblastic leukemia, yet their genetic determinants remain incompletely defined. In this study, we aimed to identify novel genetic contributors to bone toxicity and to evaluate the robustn… |
Clinical OS | 33.6 |
Clinical Result source | ClinicalTrials.gov NCT00061945 |
Clinical Data Tier / Score | A · 44 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교